United Kingdom

The Global Health Economics and Reimbursement Team are experts on estalishing reimbursement for, and demonstrating the economic value of, Abbott technologies. We work in every stage of product life – from product development to medical coding and payment. Our goal is to ensure worldwide patient access to life improving technologies through economic evidence, medical policy and provider reimbursement.


  • The National Institute of Health and Care Excellence (NICE) recommended that point‑by‑point RF ablation should be considered if drug treatment is unsuccessful, unsuitable or not tolerated in people with symptomatic paroxysmal or persistent atrial fibrillation.

    One of the reasons this recommendation was made was that point‑by‑point RF ablation was found to more cost-effective than cryoballoon ablation and other approaches to ablation.

Heart Failure

Structural Heart

National Institute for Health and Care Excellence (NICE)


  • These recommendations include special arrangements for clinical governance, consent and audit or research in OCT use.

  • The recommendations include:

    For acute iliofemoral DVT, the evidence on efficacy is limited in quality and quantity, therefore this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

    For distal DVT that does not extend into the common femoral vein, the evidence on efficacy is inconclusive, therefore this procedure should only be used in the context of research.

    These recommendations include special arrangements for clinical governance, consent and audit or research in the procedure of percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions.

We’re Here to Help

Please call us at +44 79-2-082-4756 or email us if you need assistance or have any health economics or reimbursement questions.

This material and the information contained herein is for general information purposes only and is not intended, and does not constitute, legal, reimbursement, business, clinical, or other advice. Furthermore, it is not intended to and does not constitute a representation or guarantee of reimbursement, payment, or charge, or that reimbursement or other payment will be received. It is not intended to increase or maximize payment by any payer. Similarly, nothing in this document should be viewed as instructions for selecting any particular code, and Abbott does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding and obtaining payment/reimbursement remains with the customer. This includes the responsibility for accuracy and veracity of all coding and claims submitted to third-party payers. In addition, the customer should note that laws, regulations, and coverage policies are complex and are updated frequently, and, therefore, the customer should check with its local carriers or intermediaries often and should consult with legal counsel or a financial, coding, or reimbursement specialist for any questions related to coding, billing, reimbursement or any related issues. This material reproduces information for reference purposes only. It is not provided or authorized for marketing use.

MAT-2008271 v4.0